PuSH - Publication Server of Helmholtz Zentrum München

Export: TXT Text RIS Endnote (RIS) BIB BibTeX
Schlosser, E.* ; Mueller, M.* ; Fischer, S.* ; Basta, S.* ; Busch, D.H. ; Gander, B.* ; Groettrup, M.*

TLR ligands and antigen need to be coencapsulated into the same biodegradable microsphere for the generation of potent cytotoxic T lymphocyte responses.

Vaccine 26, 1626-1637 (2008)
DOI
Open Access Green as soon as Postprint is submitted to ZB.
Dendritic cells phagocytose pathogens leading to maturation and cross-presentation on MHC class I. We found that the efficiency of cross-priming in mice after vaccination with biodegradable poly(D,L-lactide-co-glycolide) microspheres (MSs) was enhanced when ovalbumin was coencapsulated together with either a CpG oligonucleotide or polyI:C as compared to co-inoculation of ovalbumin-bearing MS with soluble or separately encapsulated adjuvants. A single immunization with MS containing coencaspsulated CpG and ovalbumin yielded 9% SIINFEKL/H-2K(b) tetramer positive CTLs, production of IFN-gamma, efficient cytolysis, and protection from vaccinia virus infection. Taken together, coencapsulation of adjuvant and antigen is an important paradigm for the generation of potent CTL responses.
Impact Factor
Scopus SNIP
Web of Science
Times Cited
Scopus
Cited By
Altmetric
3.377
1.270
163
227
Tags
Annotations
Special Publikation
Hide on homepage

Edit extra information
Edit own tags
Private
Edit own annotation
Private
Hide on publication lists
on hompage
Mark as special
publikation
Publication type Article: Journal article
Document type Scientific Article
Keywords Biodegradable microspheres; Viral infection; Cytotoxic T cells
Language english
Publication Year 2008
HGF-reported in Year 0
ISSN (print) / ISBN 0264-410X
e-ISSN 1358-8745
Journal Vaccine
Quellenangaben Volume: 26, Issue: 13, Pages: 1626-1637 Article Number: , Supplement: ,
Publisher Elsevier
Reviewing status Peer reviewed
Institute(s) CCG Immune Monitoring (Platform) (IMI-KIM)
Institute of Virology (VIRO)
POF-Topic(s)
30203 - Molecular Targets and Therapies
Research field(s)
Immune Response and Infection
PSP Element(s) G-520400-001
G-502700-002
DOI 10.1016/j.vaccine.2008.01.030
Erfassungsdatum 2008-09-10
[➜Report correction]